Bausch & Lomb eyes global options as it cuts staff
This article was originally published in Clinica
Eye care company Bausch & Lomb is to cut 7% of its workforce by consolidating its contact lens manufacturing operations. It has highlighted other areas where further savings can be made and has also authorised the repurchase of five million shares. The value of B&L's shares rose by nearly 11% to $60.7 on the news, with a trading volume of nearly double the daily average.
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.